1
|
Stępniewska K, Ożarowska A, Busse P, Bobrek R, Zehtindjiev P, Ilieva M, Meissner W. Autumn migration strategy of juvenile great reed warblers Acrocephalus arundinaceus on the eastern European flyway: a spatiotemporal pattern of accumulation and utilisation of energy stores. The European Zoological Journal 2020. [DOI: 10.1080/24750263.2020.1814882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- K. Stępniewska
- Avian Ecophysiology Unit, Department of Vertebrate Ecology and Zoology, Faculty of Biology, University of Gdańsk, Gdańsk, Poland
- Bird Migration Research Station, Faculty of Biology, University of Gdańsk, Gdańsk, Poland
| | - A. Ożarowska
- Avian Ecophysiology Unit, Department of Vertebrate Ecology and Zoology, Faculty of Biology, University of Gdańsk, Gdańsk, Poland
| | - P. Busse
- Bird Migration Research Foundation, Choczewo, Poland
| | - R. Bobrek
- Rakutowskie Bird Ringing Station, Students Naturalists Association of the Jagiellonian University, Faculty of Biology, Jagiellonian University, Kraków, Poland
| | - P. Zehtindjiev
- Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, Sofia, Bulgaria
| | - M. Ilieva
- Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, Sofia, Bulgaria
| | - W. Meissner
- Avian Ecophysiology Unit, Department of Vertebrate Ecology and Zoology, Faculty of Biology, University of Gdańsk, Gdańsk, Poland
| |
Collapse
|
2
|
Riedl M, Cicardi M, Hao J, Lu P, Li H, Manning M, Bernstein J, Busse P, Tachdjian R, Gower R, Wedner H. P159 LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY. Ann Allergy Asthma Immunol 2019. [DOI: 10.1016/j.anai.2019.08.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
3
|
Abstract
Objectives Intra-articular injections of local anaesthetics (LA), glucocorticoids (GC), or hyaluronic acid (HA) are used to treat osteoarthritis (OA). Contrast agents (CA) are needed to prove successful intra-articular injection or aspiration, or to visualize articular structures dynamically during fluoroscopy. Tranexamic acid (TA) is used to control haemostasis and prevent excessive intra-articular bleeding. Despite their common usage, little is known about the cytotoxicity of common drugs injected into joints. Thus, the aim of our study was to investigate the effects of LA, GC, HA, CA, and TA on the viability of primary human chondrocytes and tenocytes in vitro. Methods Human chondrocytes and tenocytes were cultured in a medium with three different drug dilutions (1:2; 1:10; 1:100). The following drugs were used to investigate cytotoxicity: lidocaine hydrochloride 1%; bupivacaine 0.5%; triamcinolone acetonide; dexamethasone 21-palmitate; TA; iodine contrast media; HA; and distilled water. Normal saline served as a control. After an incubation period of 24 hours, cell numbers and morphology were assessed. Results Using LA or GC, especially triamcinolone acetonide, a dilution of 1:100 resulted in only a moderate reduction of viability, while a dilution of 1:10 showed significantly fewer cell counts. TA and CA reduced viability significantly at a dilution of 1:2. Higher dilutions did not affect viability. Notably, HA showed no effects of cytotoxicity in all drug dilutions. Conclusion The toxicity of common intra-articular injectable drugs, assessed by cell viability, is mainly dependent on the dilution of the drug being tested. LA are particularly toxic, whereas HA did not affect cell viability. Cite this article: P. Busse, C. Vater, M. Stiehler, J. Nowotny, P. Kasten, H. Bretschneider, S. B. Goodman, M. Gelinsky, S. Zwingenberger. Cytotoxicity of drugs injected into joints in orthopaedics. Bone Joint Res 2019;8:41–48. DOI: 10.1302/2046-3758.82.BJR-2018-0099.R1.
Collapse
Affiliation(s)
- P Busse
- University Center for Orthopaedics and Traumatology, and Center for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany
| | - C Vater
- University Center for Orthopaedics and Traumatology, and Center for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany
| | - M Stiehler
- University Center for Orthopaedics and Traumatology, and Center for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany
| | - J Nowotny
- University Center for Orthopaedics and Traumatology, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany
| | - P Kasten
- Orthopädisch-Chirurgisches Centrum Tübingen, Tübingen, Germany
| | - H Bretschneider
- University Center for Orthopaedics and Traumatology, and Center for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany
| | - S B Goodman
- Departments of Orthopaedic Surgery and Bioengineering, Stanford University, Stanford, California, USA
| | - M Gelinsky
- Center for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany
| | - S Zwingenberger
- University Center for Orthopaedics and Traumatology, and Center for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany
| |
Collapse
|
4
|
Lumry W, Busse P, Lu P, Jain G, Nurse C, Maurer M. SUBCUTANEOUS SELF-ADMINISTRATION OF LANADELUMAB FOR PROPHYLACTIC TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE). Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.186] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Tachdjian R, Anderson J, Busse P, Johnston D, Kiani S, Nurse C, Paes K. LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Riedl MA, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein J, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon AP, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston DT, Craig T, Launay D, Li HH, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner HJ, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan W, Maurer M. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. Allergy 2018; 73:1871-1880. [PMID: 29688579 PMCID: PMC6175137 DOI: 10.1111/all.13466] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/12/2018] [Indexed: 12/02/2022]
Abstract
Background Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐INH‐HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS‐2) evaluated the efficacy and safety of prophylactic avoralstat 300 or 500 mg compared with placebo. Methods OPuS‐2 was a Phase 3, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Subjects were administered avoralstat 300 mg, avoralstat 500 mg, or placebo orally 3 times per day for 12 weeks. The primary efficacy endpoint was the angioedema attack rate based on adjudicator‐confirmed attacks. Results A total of 110 subjects were randomized and dosed. The least squares (LS) mean attack rates per week were 0.589, 0.675, and 0.593 for subjects receiving avoralstat 500 mg, avoralstat 300 mg, and placebo, respectively. Overall, 1 subject in each of the avoralstat groups and no subjects in the placebo group were attack‐free during the 84‐day treatment period. The LS mean duration of all confirmed attacks was 25.4, 29.4, and 31.4 hours for the avoralstat 500 mg, avoralstat 300 mg, and placebo groups, respectively. Using the Angioedema Quality of Life Questionnaire (AE‐QoL), improved QoL was observed for the avoralstat 500 mg group compared with placebo. Avoralstat was generally safe and well tolerated. Conclusions Although this study did not demonstrate efficacy of avoralstat in preventing angioedema attacks in C1‐INH‐HAE, it provided evidence of shortened angioedema episodes and improved QoL in the avoralstat 500 mg treatment group compared with placebo.
Collapse
Affiliation(s)
- M. A. Riedl
- Division of Rheumatology; Allergy & Immunology; University of California San Diego; San Diego CA USA
| | - E. Aygören-Pürsün
- Department for Children and Adolescents; University Hospital Frankfurt; Frankfurt Germany
| | - J. Baker
- Baker Allergy Asthma Dermatology Research Center; Portland OR USA
| | - H. Farkas
- 3rd Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - J. Anderson
- Clinical Research Center of Alabama; Birmingham AL USA
| | - J. A. Bernstein
- Department of Internal Medicine; University of Cincinnati; Cincinnati OH USA
| | - L. Bouillet
- Internal Medicine; National Reference Centre of Angioedema; Grenoble University Hospital; Grenoble France
| | - P. Busse
- Division of Clinical Immunology and Allergy; Department of Medicine; Icahn School of Medicine at Mount Sinai; New York NY USA
| | - M. Manning
- Medical Research of Arizona; Allergy; Asthma & Immunology Associates; Scottsdale AZ USA
| | - M. Magerl
- Dermatology, Venerology and Allergology; Charite - Universitätsmedizin Berlin; Berlin Germany
| | - M. Gompels
- Immunology; North Bristol NHS Trust; Bristol UK
| | - A. P. Huissoon
- Department of Allergy and Immunology; Heartlands Hospital; Birmingham UK
| | - H. Longhurst
- Immunology; Addenbrookes Hospital; Cambridge University Hospitals; Cambridge UK
| | - W. Lumry
- Allergy and Asthma Research Associates Research Center; Dallas TX USA
| | - B. Ritchie
- Division of Hematology; Department of Medicine; University of Alberta; Edmonton AB Canada
| | - R. Shapiro
- Immunology; Midwest Immunology Clinic; Plymouth MN USA
| | - D. Soteres
- Asthma and Allergy Associates PC; Colorado Springs CO USA
| | - A. Banerji
- Division of Rheumatology; Allergy& Immunology; Department of Medicine; Massachusetts General Hospital; Harvard Medical School; Boston MA USA
| | - M. Cancian
- Department of Medicine; University of Padova; Padova Italy
| | | | - T. J. Craig
- Department of Medicine and Pediatrics; Penn State Hershey Allergy Asthma, and Immunology; Hershey PA USA
| | - D. Launay
- Internal Medicine; CHRU Lille; France France
| | - H. H. Li
- Institute for Asthma and Allergy; Chevy Chase MD USA
| | - M. Liebhaber
- Allergy and Immunology; Sansum Clinic; Santa Barbara CA USA
| | - T. Nickel
- Allergy & Immunology; Allergy Clinic of Tulsa; Tulsa OK USA
| | | | - W. Rae
- Allergy & Clinical Immunology; University Hospital Southampton NHS Foundation Trust; Southampton UK
| | - R. Schrijvers
- Laboratory of Clinical Immunology; KU Leuven; Leuven Belgium
| | - M. Triggiani
- Division of Allergy and Clinical Immunology; University of Salerno; Salerno Italy
| | - H. J. Wedner
- Division of Allergy and Immunology; Washington University School of Medicine; St. Louis MO USA
| | - S. Dobo
- Biocryst Pharmaceuticals; Durham NC USA
| | | | | | - L. Fang
- Statistics; PharStat, Inc.; Raleigh NC USA
| | - P. Collis
- Biocryst Pharmaceuticals; Durham NC USA
| | | | - M. Maurer
- Department of Dermatology and Allergy; Charité - Universitätsmedizin Berlin; Berlin Germany
| |
Collapse
|
7
|
Toyama M, Diez-Canseco F, Busse P, Del Mastro I, Miranda JJ. Design and content validation of a set of SMS to promote seeking of specialized mental health care within the Allillanchu Project. Glob Health Epidemiol Genom 2018; 3:e2. [PMID: 29868227 PMCID: PMC5870406 DOI: 10.1017/gheg.2017.18] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 12/11/2017] [Accepted: 12/14/2017] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND The aim of this study was to design and develop a set of, short message service (SMS) to promote specialized mental health care seeking within the framework of the Allillanchu Project. METHODS The design phase consisted of 39 interviews with potential recipients of the SMS, about use of cellphones, and perceptions and motivations towards seeking mental health care. After the data collection, the research team developed a set of seven SMS for validation. The content validation phase consisted of 24 interviews. The participants answered questions regarding their understanding of the SMS contents and rated its appeal. RESULTS The seven SMS subjected to content validation were tailored to the recipient using their name. The reminder message included the working hours of the psychology service at the patient's health center. The motivational messages addressed perceived barriers and benefits when seeking mental health services. The average appeal score of the seven SMS was 9.0 (SD±0.4) of 10 points. Participants did not make significant suggestions to change the wording of the messages. CONCLUSIONS Five SMS were chosen to be used. This approach is likely to be applicable to other similar low-resource settings, and the methodology used can be adapted to develop SMS for other chronic conditions.
Collapse
Affiliation(s)
- M. Toyama
- CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - F. Diez-Canseco
- CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - P. Busse
- Instituto de Investigación Científica, Universidad de Lima, Lima, Peru
| | - I. Del Mastro
- Facultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - J. J. Miranda
- CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru
| |
Collapse
|
8
|
Dillon MBC, Schulten V, Oseroff C, Paul S, Dullanty LM, Frazier A, Belles X, Piulachs MD, Visness C, Bacharier L, Bloomberg GR, Busse P, Sidney J, Peters B, Sette A. Different Bla-g T cell antigens dominate responses in asthma versus rhinitis subjects. Clin Exp Allergy 2015; 45:1856-67. [PMID: 26414909 PMCID: PMC4654660 DOI: 10.1111/cea.12643] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 07/29/2015] [Accepted: 08/19/2015] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND OBJECTIVE The allergenicity of several German cockroach (Bla-g) antigens at the level of IgE responses is well established. However, less is known about the specificity of CD4+ TH responses, and whether differences exist in associated magnitude or cytokine profiles as a function of disease severity. METHODS Proteomic and transcriptomic techniques were used to identify novel antigens recognized by allergen-specific T cells. To characterize different TH functionalities of allergen-specific T cells, ELISPOT assays with sets of overlapping peptides covering the sequences of known allergens and novel antigens were employed to measure release of IL-5, IFNγ, IL-10, IL-17 and IL-21. RESULTS Using these techniques, we characterized TH responses in a cohort of adult Bla-g-sensitized subjects, either with (n = 55) or without (n = 17) asthma, and nonsensitized controls (n = 20). T cell responses were detected for ten known Bla-g allergens and an additional ten novel Bla-g antigens, representing in total a 5-fold increase in the number of antigens demonstrated to be targeted by allergen-specific T cells. Responses of sensitized individuals regardless of asthma status were predominantly TH 2, but higher in patients with diagnosed asthma. In asthmatic subjects, Bla-g 5, 9 and 11 were immunodominant, while, in contrast, nonasthmatic-sensitized subjects responded mostly to Bla-g 5 and 4 and the novel antigen NBGA5. CONCLUSIONS Asthmatic and nonasthmatic cockroach-sensitized individuals exhibit similar TH 2-polarized responses. Compared with nonasthmatics, however, asthmatic individuals have responses of higher magnitude and different allergen specificity.
Collapse
Affiliation(s)
- M B C Dillon
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| | - V Schulten
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| | - C Oseroff
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| | - S Paul
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| | - L M Dullanty
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| | - A Frazier
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| | - X Belles
- Institut de Biologia Evolutiva (CSIC-Universitat Pompeu Fabra), Barcelona, Spain
| | - M D Piulachs
- Institut de Biologia Evolutiva (CSIC-Universitat Pompeu Fabra), Barcelona, Spain
| | - C Visness
- Federal Systems Division, Rho Inc., Chapel Hill, NC, USA
| | - L Bacharier
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - G R Bloomberg
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - P Busse
- Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai School of Medicine, New York, NY, USA
| | - J Sidney
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| | - B Peters
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| | - A Sette
- La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
| |
Collapse
|
9
|
Chan A, Weyman E, Goldsmith T, Wirth L, Clark J, Busse P, Holman A, Delaney T. A Phase II Trial of Proton Radiotherapy with Chemotherapy for Nasopharyngeal Carcinoma. Skull Base Surg 2014. [DOI: 10.1055/s-0034-1384022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Birmingham J, Srivastava K, Li X, Busse P. Age-related Differences in Antigen Sensitization and the Allergic Airway Responses in Acute and Resolved Viral Respiratory Infection. J Allergy Clin Immunol 2012. [DOI: 10.1016/j.jaci.2011.12.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Tishler R, Lorch J, Sher D, Clark J, Chan A, Suda M, Balboni T, Busse P, Haddad R, Wirth L. A Phase I/II Study of Concurrent Abraxane, Carboplatin and IMRT for Locally Advanced Squamous Cell Cancer of the Head and Neck (LASCCHN). Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.796] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Wang J, Truong M, Adams J, Cianchetti M, Liebsch N, Busse P, McIntyre J, Chan A. A Comparison of Definitive with Postoperative Proton Beam Therapy for Locally Advanced Sinonasal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Wear C, Wang J, Truong M, Liebsch N, Busse P, Clark J, Chan A. Preliminary Results of a Phase II Trial with Proton Beam Therapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
|
15
|
Jiang SB, Berbeco R, Wolfgang J, Sharp G, Doppke K, Neicu T, Chen Y, Busse P, Chen G. TH-C-J-6B-09: Image-Guided Respiration-Gated Treatment. Med Phys 2005. [DOI: 10.1118/1.1998653] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
16
|
Sonis ST, Scherer J, Phelan S, Lucey CA, Barron JE, O'Donnell KE, Brennan RJ, Pan H, Busse P, Haley JD. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif 2002; 35 Suppl 1:93-102. [PMID: 12139712 PMCID: PMC6496665 DOI: 10.1046/j.1365-2184.35.s1.10.x] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Oral mucositis is a common, dose-limiting, acute toxicity of radiation therapy administered for the treatment of cancers of the head and neck. Accumulating data would suggest that the pathogenesis of mucositis is complex and involves the sequential interaction of all cell types of the oral mucosa, as well as a number of cytokines and elements of the oral environment. While a number of studies have reported on gene expression of particular cell types in response to radiation, the overall response of irradiated mucosa has only been evaluated in a limited way. The present study was undertaken to evaluate the expression of a target group of genes using RNA quantification assays and, more broadly, to assess patterns of mucosal gene expression using DNA microarray hybridization. Our results demonstrate the sequential upregulation of a series of genes that, when taken collectively, suggest an intricate functional interaction.
Collapse
Affiliation(s)
- S T Sonis
- Division of Oral Medicine, Oral and Maxillofacial Surgery and Dentistry, Brigham and Women's Hospital and the Department of Otal Medicine and Diagnostic Sciences, Harvard School of Dental Medicine, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Colevas AD, Read R, Thornhill J, Adak S, Tishler R, Busse P, Li Y, Posner M. Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2001; 51:599-604. [PMID: 11597798 DOI: 10.1016/s0360-3016(01)01688-1] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
PURPOSE Treatment of head-and-neck cancer patients with surgery, radiotherapy (RT), and chemotherapy has been associated with posttherapy hypothyroidism (HT). We evaluated the rate of posttherapy HT in patients with locally advanced squamous cell carcinoma of the head and neck, treated with multimodality therapy to determine which factors might predict this condition and at what interval the condition developed. METHODS We reviewed the prospectively collected thyroid function data of patients treated with sequential chemotherapy, RT, and neck dissection. The incidence of posttherapy HT was estimated. The patient, tumor, and treatment factors possibly associated with HT were evaluated. RESULTS Of 203 patients, 118 had data adequate for evaluation. HT developed in 45% at a median of 24.4 months after therapy. HT occurred in 14% and 27% of patients at 6 months and 1 year after treatment, respectively. Univariate and multivariate analyses of sex, age, RT dose, RT fractionation, T and N stage, tumor site, and neck dissection failed to identify a clinically relevant risk factor. CONCLUSIONS A high number of patients undergoing aggressive organ-sparing multimodality therapy for advanced squamous cell carcinoma of the head and neck are at risk for subsequent HT. We recommend that all patients definitively irradiated to the head and neck region undergo frequent serum thyroid-stimulating hormone screening for HT, beginning 6 months after RT.
Collapse
Affiliation(s)
- A D Colevas
- Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston MA, USA.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Sauerwein W, Hideghéy K, Moss R, Busse P, Harling O, Zamenhoff R, Coderre J, Nakagawa Y, Pignol JP. Past, present and future trends of boron neutron capture therapy (BNCT). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)80773-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Zuo CS, Prasad PV, Busse P, Tang L, Zamenhof RG. Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy. Med Phys 1999; 26:1230-6. [PMID: 10435522 PMCID: PMC4470577 DOI: 10.1118/1.598617] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Noninvasive in vivo quantitation of boron is necessary for obtaining pharmacokinetic data on candidate boronated delivery agents developed for boron neutron capture therapy (BNCT). Such data, in turn, would facilitate the optimization of the temporal sequence of boronated drug infusion and neutron irradiation. Current approaches to obtaining such pharmacokinetic data include: positron emission tomography employing F-18 labeled boronated delivery agents (e.g., p-boronophenylalanine), ex vivo neutron activation analysis of blood (and very occasionally tissue) samples, and nuclear magnetic resonance (NMR) techniques. In general, NMR approaches have been hindered by very poor signal to noise achieved due to the large quadrupole moments of B-10 and B-11 and (in the case of B-10) very low gyromagnetic ratio, combined with low physiological concentrations of these isotopes under clinical conditions. This preliminary study examines the feasibility of proton NMR spectroscopy for such applications. We have utilized proton NMR spectroscopy to investigate the detectability of p-boronophenylalanine fructose (BPA-f) at typical physiological concentrations encountered in BNCT. BPA-f is one of the two boron delivery agents currently undergoing clinical phase-I/II trials in the U.S., Japan, and Europe. This study includes high-resolution 1H spectroscopic characterization of BPA-f to identify useful spectral features for purposes of detection and quantification. The study examines potential interferences, demonstrates a linear NMR signal response with concentration, and presents BPA NMR spectra in ex vivo blood samples and in vivo brain tissues.
Collapse
Affiliation(s)
- C S Zuo
- Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
| | | | | | | | | |
Collapse
|
20
|
Shibata D, Hyland W, Busse P, Kim HK, Sentovich SM, Steele G, Bleday R. Immediate reconstruction of the perineal wound with gracilis muscle flaps following abdominoperineal resection and intraoperative radiation therapy for recurrent carcinoma of the rectum. Ann Surg Oncol 1999; 6:33-7. [PMID: 10030413 DOI: 10.1007/s10434-999-0033-4] [Citation(s) in RCA: 196] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND Morbidity associated with a nonhealing perineal wound is the most common complication following proctectomy, particularly in the setting of recurrent carcinoma of the rectum and radiation therapy. Immediate reconstruction using the gracilis myocutaneous and muscle flaps significantly reduces the incidence of major infection associated with perineal wound closure. The purpose of this study was to assess the value of immediate reconstruction of the perineal wound using a gracilis flap in patients undergoing abdominoperineal resection and intraoperative radiation therapy. METHODS This study retrospectively reviewed our experience with immediate pelvic reconstruction using gracilis muscle flaps for patients undergoing rectal extirpation and irradiation for recurrent carcinoma of the rectum. From 1990 to 1995, 16 patients underwent abdominoperineal resection (APR) or pelvic exenteration accompanied by immediate wound closure with unilateral or bilateral gracilis muscle flaps. Morbidity and mortality outcomes were compared to those of 24 patients from our institution who, between 1988 and 1992, underwent proctectomy and irradiation for recurrent rectal carcinoma with primary closure of the perineal wound. RESULTS Major complications (i.e., major infection requiring hospitalization and/or operation) occurred in 2 (12%) of the patients with gracilis flaps versus 11 (46%) of the patients with primary closure (P = .028 by chi2 analysis for flap vs. primary closure). Minor complications (i.e., persistent sinus and subcutaneous abscess) occurred in 4 (25%) of the patients with gracilis flaps versus 5 (21%) of those with primary closure. CONCLUSION Immediate perineal reconstruction using the gracilis myocutaneous flap following proctectomy and irradiation for recurrent rectal carcinoma significantly reduces the incidence of major infection associated with perineal wound closure.
Collapse
Affiliation(s)
- D Shibata
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | | | | | | | | | | |
Collapse
|
21
|
Affiliation(s)
- P Busse
- NAPWA South Africa, Western Cape
| |
Collapse
|
22
|
Posner M, Dreyfuss A, Norris C, Costello R, Rossi R, Poulin M, Clark J, Busse P. 421 A phase II trial of docetaxel in squamous cell cancer of the head and neck. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95674-u] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Jessup JM, Steele G, Mayer RJ, Posner M, Busse P, Cady B, Stone M, Jenkins R, Osteen R. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993; 128:559-64. [PMID: 8098206 DOI: 10.1001/archsurg.1993.01420170093014] [Citation(s) in RCA: 133] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The purposes of this study were to determine whether continuous infusion of fluorouracil combined with external-beam radiation therapy improved the resectability and survival of patients with pancreatic carcinoma. Sixteen patients with unresectable disease confined to the pancreas and celiac nodes were treated, and their outcome was compared with that of 24 patients with potentially resectable disease who were treated concurrently. The neoadjuvant therapy was completed with acceptably few toxic effects but with only a minor decrease in tumor size. Two patients underwent resection and remained free of disease 20 and 22.5 months later. However, the median survival of the entire neoadjuvant group was 8 months. All 24 patients with potentially resectable carcinoma underwent surgical exploration. Fifteen of the 24 patients underwent resection and survived a median of 12.5 months. Neoadjuvant chemoradiation may have improved outcome and resectability for two (12.5%) of 16 patients with unresectable pancreatic carcinoma, but more effective therapy options must be developed to improve outcome.
Collapse
Affiliation(s)
- J M Jessup
- Department of Surgery, New England Deaconess Hospital, Boston, Mass
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Posner MR, Bleday R, Huberman M, Jessup JM, Busse P, Steele G. Impact of combined modality therapy on the treatment of adenocarcinoma of the colon. Semin Surg Oncol 1993; 9:33-8. [PMID: 8356383 DOI: 10.1002/ssu.2980090107] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
An emphasis on careful surgical staging of adenocarcinoma of the colon has improved the predictive value of tumor staging systems. As a result of improved staging and carefully conducted randomized clinical trials, adjuvant therapy of locally advanced colon cancer, based on 5-fluorouracil chemotherapy, has been proven to substantially reduce recurrence rates and significantly increase overall survival for selected patients. Improved treatments and schedules are currently being studied in randomized trials and may increase the efficacy of this adjuvant therapy. Radiation therapy has not as yet been integrated into the adjuvant treatment of colon carcinoma. The application of a combined approach of surgery and chemotherapy in selected patients with liver metastases may also improve cure rates and long-term survival. The developing understanding of molecular determinants for the biological behavior of these cancers will increase the opportunities to identify, on the one hand, those patients who will benefit from specific therapies, and, on the other hand, new therapeutic strategies and treatments.
Collapse
Affiliation(s)
- M R Posner
- Department of Medicine, New England Deaconess Hospital, Boston, MA 02215
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
The goals of the conservative management of adenocarcinoma of the distal rectum are to preserve rectal sphincter function and achieve excellent local tumor control. Multimodality therapy for more advanced disease suggests that these goals will be met by conservative surgery combined with radiation therapy and chemotherapy. Over 100 patients with T0-3 N0-1 lesions have been treated in prospective single institution trials with either local excision or anterior resection with coloanal anastomosis, usually combined with chemotherapy and radiotherapy. The typical criteria for local excision have been for lesions to be 4.0 cm or less, mobile, and not poorly differentiated or mucinous. Patients with larger or more advanced lesions may undergo anterior resection with coloanal anastomosis. Following resection, radiotherapy is delivered to the pelvis and tumor bed often with concomitant chemotherapy. The overall rate of local failure in the trials in which local excision is performed with postoperative chemoradiotherapy is 3% for T1 lesions, 5% for T2 lesions, and 30% for T3 lesions with a median follow-up of at least 25 months. Local failure in patients with a coloanal anastomosis is 9% overall. Salvage was successful in about half of the patients who failed locally. Importantly, nearly all patients remained continent. These institutional studies show that sphincter preservation can be used in patients who are objectively selected for this procedure. However, before this multimodality approach may be considered standard therapy the rate of local control must be confirmed in a large, Phase II, multicenter, prospective trial such as that now underway in many of the cooperative groups.
Collapse
Affiliation(s)
- J M Jessup
- Department of Surgery, New England Deaconess Hospital, Boston, MA 02215
| | | | | | | |
Collapse
|
26
|
Busse P, Beard C, Clark J, Norris C, Dreyfuss A, Lucarini J, Rossi R, Casey D, Miller D. Radiation as primary site management following induction chemotherapy with CIS-platinum, 5-FU, and leucovorin (PFL). Int J Radiat Oncol Biol Phys 1992. [DOI: 10.1016/0360-3016(92)90260-o] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
27
|
Steele G, Busse P, Huberman MS, LeClair JM, Falchuk ZM, Mayer RJ, Bothe A, Ravikumar TS, Stone M, Jessup JM. A pilot study of sphincter-sparing management of adenocarcinoma of the rectum. Arch Surg 1991; 126:696-701; discussion 701-2. [PMID: 2039356 DOI: 10.1001/archsurg.1991.01410300038005] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
After analysis of 26 prospectively accrued patients with distal rectal adenocarcinomas who underwent sphincter preservation treatment, we have concluded that tumors that invade only the submucosa can safely be treated with surgery alone and that tumors that invade the muscularis or further can be safely treated with surgery combined with chemoradiotherapy. None of the patients had either local or distant recurrence, with a median follow-up of 21 months. All patients have been fully continent. The results, although preliminary, imply that resection of distal rectal adenocarcinoma with sphincter preservation, and adjuvant therapy when appropriate, have achieved local and distant control equal to the conventional Miles' abdominoperineal resection, but without the need for a permanent colostomy.
Collapse
Affiliation(s)
- G Steele
- Department of Surgery, New England Deaconess Hospital, Harvard Medical School, Boston, MA 02215
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
|